Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
October, 2026
October 2026
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  
A Game-Changer by Roche and Chugai | NXT007: For Hemophilia A, Without Inhibitors
The National Bleeding Disorders Foundation / X
Jul 5, 2025, 17:47

A Game-Changer by Roche and Chugai | NXT007: For Hemophilia A, Without Inhibitors

The National Bleeding Disorders Foundation (NBDF) posted in appreciation of Roche and Chugai on X:

”Roche and Chugai recently presented new data on NXT007, an investigational bispecific antibody therapy for people with hemophilia A without inhibitors. Phase III studies are planned to begin in 2026.”

To learn more about this advancement, follow the link.

The promising findings—because we can never have too many early-stage breakthroughs—were shared during recent scientific presentations, hinting at NXT007’s potential to once again reshape prophylactic treatment for this ever-hopeful patient population.

Roche and Chugai have recently unveiled new data on NXT007, an investigational bispecific antibody therapy designed for individuals with hemophilia A without inhibitors.

NXT007, engineered to mimic the function of activated factor VIII, builds upon the success of emicizumab and is designed to offer improved pharmacokinetics and efficacy.

Looking ahead, Phase III clinical trials of NXT007 are expected to begin in 2026, marking a significant step forward in evaluating the therapy’s long-term potential and its role in reducing bleeding episodes and improving quality of life for patients!

A Game-Changer by Roche and Chugai | NXT007: For Hemophilia A, Without Inhibitors

Find more on drug advancements in the field of Hemophilia management in Hemostasis Today.

bispecific antibody Emicizumab Headlines Health Hematology Hemophilia Hemostasis Today Medicine National Bleeding Disorders Foundation NBDF NXT007 Roche and Chugai
NewsFeed